Date: 2014-11-20
Type of information: Grant
Company: Modern Biosciences (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £2.4 million (€3 million)
Funding type: grant
Planned used: The award will provide support for Modern Biosciences’ lead programme for the development of novel bone-protective compounds in the treatment of rheumatoid arthritis.
Others: * On November 20, 2014, Modern Biosciences announced that the company has been awarded a grant of up to £2.4 million by the UK government-backed Biomedical Catalyst. The Biomedical Catalyst, launched in 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector. Today’s award to MBS will help fund the clinical development of a candidate molecule through Phase 1 clinical studies and provide evidence from patients for the drug’s efficacy and safety. This represents the second award of a Biomedical Catalyst grant to MBS in relation to the RA programme, the first of which was announced in 2012.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
